非ST段抬高型急性冠脉综合征侵入性策略时机:随机对照试验荟萃分析
结果显示早期侵入性策略未显著降低全因死亡、心肌梗死、心衰入院、再次血运重建、大出血或卒中风险,但显著减少再发缺血和缩短住院时间。
要点
- 早期侵入性策略未显著改善全因死亡等硬终点。
- 早期侵入性策略显著降低再发缺血风险(RR 0.57)。
- 早期侵入性策略缩短住院时间(中位差-22小时)。
核心结论
- 在非ST段抬高型急性冠脉综合征全人群患者中,与延迟侵入性策略相比,早期侵入性策略不降低全因死亡、心肌梗死、心衰入院或再次血运重建风险,也不增加大出血或卒中风险。
- 早期侵入性策略显著降低再发缺血风险并缩短住院时间。
研究设计与样本
- 系统检索MEDLINE、Embase和Cochrane Central Register of Controlled Trials,纳入比较早期与延迟侵入性策略的随机对照试验。
- 主要结局为全因死亡,次要结局包括心肌梗死、再发缺血、心衰入院、再次血运重建、大出血、卒中和住院时间。
- 研究注册于PROSPERO(CRD42021246131)。
主要发现
- 全因死亡风险无显著差异(RR 0.90,95%CI 0.78-1.04)。
- 心肌梗死风险无显著差异(RR 0.86,95%CI 0.63-1.16)。
- 心衰入院风险无显著差异(RR 0.66,95%CI 0.43-1.03)。
- 再次血运重建风险无显著差异(RR 1.04,95%CI 0.88-1.23)。
- 大出血风险无显著差异(RR 0.86,95%CI 0.68-1.09);卒中风险无显著差异(RR 0.95,95%CI 0.59-1.54)。
临床怎么用
- 对于非ST段抬高型急性冠脉综合征患者,早期侵入性策略不能改善死亡、心肌梗死等硬终点,临床决策需权衡再发缺血减少与住院时间缩短的获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The optimal timing of an invasive strategy (IS) in non-ST-elevation acute coronary syndrome (NSTE-ACS) is controversial. Recent randomized controlled trials (RCTs) and long-term follow-up data have yet to be included in a contemporary meta-analysis. METHODS AND RESULTS: A systematic review of RCTs that compared an early IS vs. delayed IS for NSTE-ACS was conducted by searching MEDLINE, Embase, and Cochrane Central Register of Controlled Trials. A meta-analysis was performed by pooling relative risks (RRs) using a random-effects model. The primary outcome was all-cause mortality. Secondary outcomes included myocardial infarction (MI), recurrent ischaemia, admission for heart failure (HF), repeat re-vascularization, major bleeding, stroke, and length of hospital stay. This study was registered with PROSPERO (CRD42021246131). Seventeen RCTs with outcome data from 10 209 patients were included. No significant differences in risk for all-cause mortality [RR: 0.90, 95% confidence interval (CI): 0.78-1.04], MI (RR: 0.86, 95% CI: 0.63-1.16), admission for HF (RR: 0.66, 95% CI: 0.43-1.03), repeat re-vascularization (RR: 1.04, 95% CI: 0.88-1.23), major bleeding (RR: 0.86, 95% CI: 0.68-1.09), or stroke (RR: 0.95, 95% CI: 0.59-1.54) were observed. Recurrent ischaemia (RR: 0.57, 95% CI: 0.40-0.81) and length of stay (median difference: -22 h, 95% CI: -36.7 to -7.5 h) were reduced with an early IS. CONCLUSION: In all-comers with NSTE-ACS, an early IS does not reduce all-cause mortality, MI, admission for HF, repeat re-vascularization, or increase major bleeding or stroke when compared with a delayed IS. Risk of recurrent ischaemia and length of stay are significantly reduced with an early IS.
引用
- Kite, Kurmani, Bountziouka, et al. Timing of invasive strategy in non-ST-elevation acute coronary syndrome: a meta-analysis of randomized controlled trials. Eur Heart J. 2022. PMID: 35514079. doi:10.1093/eurheartj/ehac213
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。